Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
HD$358.90+3.46(+0.97%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.19-0.08(-29.63%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.60+1.83(+1.47%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMRNA$255.90-2.44(-0.94%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$152.99-20.20(-11.66%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$464.00-24.78(-5.07%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$439.98+3.39(+0.78%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.84+0.85(+1.06%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$758.63-36.83(-4.63%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$290.07+2.77(+0.96%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETTCPC$4.32-0.06(-1.37%)BlackRock TCP Capital Corp. Announces Third Quarter 2026 Financial Results Including Net Investment Income of $0.16 Per Share; Declares a Fourth Quarter Dividend of $0.17 Per Share8:05:07 AM ETINTC$56.82-1.46(-2.51%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,455.22-40.92(-2.74%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$316.89-8.81(-2.70%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.51+0.34(+0.74%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.67+0.81(+0.80%)Transaction in Own Shares8:00:53 AM ETIBM$255.90+1.58(+0.62%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$635.19+5.19(+0.82%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$482.88+0.69(+0.14%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$290.07+2.77(+0.96%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ET

BLTE · NASDAQ

Belite Bio, Inc

$153.98 +0.06 (+0.04%)

Company overview

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company engaged in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive Stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue, which is in Phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$6.2B
Employees
25
Headquarters
San Diego, CA
Website
belitebio.com
CEO
Yu-Hsin Lin
Listed
April 29, 2022
P/E
-60.38
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$101M
EBITDA
-$101M
Net income
-$90.3M
EPS
-$2.55
Total assets
$781M
Total debt
$429,000
Earnings yield
-1.66%

Price chart

127.26145.77164.29182.81201.32
BLTE 1D NASDAQ O156.97H156.97L150.65C153.92+1.75 (+1.15%)Vol55.66K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
BLTEBelite Bio, Inc Press release Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio Announces Uplisting to the Nasdaq Global Select Market GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio Announces Oral Presentations at Two Upcoming GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences GlobeNewswire
BLTEBelite Bio, Inc Stock news Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
BLTEBelite Bio, Inc Stock news Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross Zacks Investment Research
BLTEBelite Bio, Inc Press release Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 GlobeNewswire
BLTEBelite Bio, Inc Stock news Why Is Belite Bio Stock Soaring Friday? Benzinga
BLTEBelite Bio, Inc Stock news Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease MarketBeat
BLTEBelite Bio, Inc Stock news Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript Seeking Alpha
BLTEBelite Bio, Inc Press release Belite Bio to Participate in Four Upcoming Investor Conferences GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio to Host Virtual Commercial Day on September 2, 2026 GlobeNewswire
BLTEBelite Bio, Inc Press release Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences GlobeNewswire
BLTEBelite Bio, Inc Stock news Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript Seeking Alpha
BLTEBelite Bio, Inc Stock news Belite Bio Q2 Earnings Call Highlights MarketBeat
BLTEBelite Bio, Inc Press release Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update GlobeNewswire
BLTEBelite Bio, Inc Stock news BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA Zacks Investment Research
BLTEBelite Bio, Inc Stock news CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga
BLTEBelite Bio, Inc Press release Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 GlobeNewswire
See more
FAQ

Questions about Belite Bio, Inc

What does Belite Bio, Inc do?
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company engaged in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive Stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue, which is in Phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
What is BLTE's market cap?
Belite Bio, Inc (BLTE) is a listed stock with a live quote. The latest market cap on this page is $6.2B.
Where is Belite Bio, Inc headquartered?
Belite Bio, Inc is headquartered in San Diego, CA.
How do I get BLTE news from the API?
Call GET /v1/news?tickers=BLTE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does BLTE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BLTE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the BLTE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs